Oxaliplatin As Part of Adjuvant Therapy for Colon Cancer: More Complicated Than Once Thought
Mené sur 899 patients atteints d'un cancer du côlon de stade II, dont 315 d'âge compris entre 70 et 75 ans, cet essai évalue, du point de vue de la survie globale et de la survie sans maladie, les effets de l'ajout d'oxaliplatine à la fluoropyrimidine en traitement adjuvant
Theability of adjuvant fluorouracil-based therapy to significantly enhance survival in patients with stage III colon cancer was initially reported in 1990 and confirmed in 1995. Such an improved outcome, however, was not observedwhenfluorouracil or fluorouracil and leucovorin were administered to patients with stage II disease. Although the efficacy of adjuvant therapy for all patients with stage II colon cancer remains an area of controversy, a retrospective subset analysis suggested that those individuals who have stage II disease with clinical characteristics that are predictive for a higher likelihood of recurrence (ie, T4 lesions, bowel obstruction, tumor perforation) might benefit from adjuvant treatment...